“…Data from the first in-man studies investigating the safety and pharmacokinetics (PKs) of BI 2536 in patients with advanced tumors demonstrated that BI 2536 was well tolerated, had a favorable PK profile, and showed potential antitumor activity. [12][13][14] When BI 2536 was administered as a single intravenous (iv) infusion or a daily infusion for 3 days, the maximum tolerated doses were 200 and 60 mg/d for the single iv infusion and the 3-consecutive-day infusion, respectively. 14 The most frequently observed adverse events (AEs) consisted of nausea, anorexia, fatigue, vomiting, and mucositis and were mostly of mild to moderate intensity.…”